nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—ABCG2—Dexamethasone—psoriatic arthritis	0.0395	0.106	CbGbCtD
Nilotinib—ABCB1—Methylprednisolone—psoriatic arthritis	0.0376	0.101	CbGbCtD
Nilotinib—ABCG2—Methotrexate—psoriatic arthritis	0.0317	0.0849	CbGbCtD
Nilotinib—CYP2B6—Dexamethasone—psoriatic arthritis	0.0278	0.0743	CbGbCtD
Nilotinib—ABCB1—Betamethasone—psoriatic arthritis	0.0245	0.0655	CbGbCtD
Nilotinib—ABCB1—Prednisolone—psoriatic arthritis	0.0241	0.0646	CbGbCtD
Nilotinib—ABCB1—Prednisone—psoriatic arthritis	0.0228	0.061	CbGbCtD
Nilotinib—CYP3A4—Methylprednisolone—psoriatic arthritis	0.0225	0.0603	CbGbCtD
Nilotinib—CYP2C8—Dexamethasone—psoriatic arthritis	0.021	0.0563	CbGbCtD
Nilotinib—CYP3A4—Triamcinolone—psoriatic arthritis	0.0171	0.0457	CbGbCtD
Nilotinib—CYP2C9—Dexamethasone—psoriatic arthritis	0.0147	0.0392	CbGbCtD
Nilotinib—CYP3A4—Betamethasone—psoriatic arthritis	0.0147	0.0392	CbGbCtD
Nilotinib—CYP3A4—Prednisolone—psoriatic arthritis	0.0145	0.0387	CbGbCtD
Nilotinib—ABCB1—Dexamethasone—psoriatic arthritis	0.0142	0.0381	CbGbCtD
Nilotinib—CYP3A4—Prednisone—psoriatic arthritis	0.0137	0.0365	CbGbCtD
Nilotinib—CYP2D6—Dexamethasone—psoriatic arthritis	0.0134	0.0359	CbGbCtD
Nilotinib—ABCB1—Methotrexate—psoriatic arthritis	0.0114	0.0306	CbGbCtD
Nilotinib—CYP3A4—Dexamethasone—psoriatic arthritis	0.00852	0.0228	CbGbCtD
Nilotinib—MAPK8—skin of body—psoriatic arthritis	0.00193	0.0657	CbGeAlD
Nilotinib—CDC42BPB—tendon—psoriatic arthritis	0.00163	0.0553	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Methylprednisolone—psoriatic arthritis	0.00153	0.174	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Dexamethasone—psoriatic arthritis	0.00151	0.172	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Betamethasone—psoriatic arthritis	0.00151	0.172	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Triamcinolone—psoriatic arthritis	0.00147	0.168	CbGdCrCtD
Nilotinib—MAPK8—tendon—psoriatic arthritis	0.00147	0.05	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Prednisone—psoriatic arthritis	0.0014	0.159	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Prednisolone—psoriatic arthritis	0.00136	0.155	CbGdCrCtD
Nilotinib—MAP4K1—tendon—psoriatic arthritis	0.00134	0.0455	CbGeAlD
Nilotinib—MAPK14—skin of body—psoriatic arthritis	0.00123	0.0417	CbGeAlD
Nilotinib—BRAF—tendon—psoriatic arthritis	0.00122	0.0416	CbGeAlD
Nilotinib—HCK—tendon—psoriatic arthritis	0.00112	0.0379	CbGeAlD
Nilotinib—ABL2—tendon—psoriatic arthritis	0.00111	0.0377	CbGeAlD
Nilotinib—EPHB6—skin of body—psoriatic arthritis	0.00106	0.0362	CbGeAlD
Nilotinib—EPHA4—tendon—psoriatic arthritis	0.00101	0.0345	CbGeAlD
Nilotinib—CA3—tendon—psoriatic arthritis	0.001	0.034	CbGeAlD
Nilotinib—CA9—tendon—psoriatic arthritis	0.000959	0.0326	CbGeAlD
Nilotinib—MAPK14—tendon—psoriatic arthritis	0.000935	0.0318	CbGeAlD
Nilotinib—FGR—tendon—psoriatic arthritis	0.000931	0.0316	CbGeAlD
Nilotinib—CA14—tendon—psoriatic arthritis	0.000909	0.0309	CbGeAlD
Nilotinib—CSF1R—skin of body—psoriatic arthritis	0.000889	0.0302	CbGeAlD
Nilotinib—EPHB4—tendon—psoriatic arthritis	0.000886	0.0301	CbGeAlD
Nilotinib—EPHA2—tendon—psoriatic arthritis	0.000869	0.0296	CbGeAlD
Nilotinib—TEK—tendon—psoriatic arthritis	0.000848	0.0288	CbGeAlD
Nilotinib—EPHB6—tendon—psoriatic arthritis	0.00081	0.0276	CbGeAlD
Nilotinib—KIT—skin of body—psoriatic arthritis	0.000807	0.0274	CbGeAlD
Nilotinib—PDGFRB—skin of body—psoriatic arthritis	0.000788	0.0268	CbGeAlD
Nilotinib—PDGFRA—tendon—psoriatic arthritis	0.000768	0.0261	CbGeAlD
Nilotinib—ABL1—skin of body—psoriatic arthritis	0.000702	0.0239	CbGeAlD
Nilotinib—MAP2K5—tendon—psoriatic arthritis	0.000693	0.0236	CbGeAlD
Nilotinib—CSF1R—tendon—psoriatic arthritis	0.000676	0.023	CbGeAlD
Nilotinib—PDGFRB—tendon—psoriatic arthritis	0.0006	0.0204	CbGeAlD
Nilotinib—ABL1—tendon—psoriatic arthritis	0.000535	0.0182	CbGeAlD
Nilotinib—CA2—skin of body—psoriatic arthritis	0.000478	0.0163	CbGeAlD
Nilotinib—CA4—tendon—psoriatic arthritis	0.000439	0.0149	CbGeAlD
Nilotinib—CYP2B6—skin of body—psoriatic arthritis	0.000409	0.0139	CbGeAlD
Nilotinib—LYN—CXCR4-mediated signaling events—HLA-DRB1—psoriatic arthritis	0.000373	0.00191	CbGpPWpGaD
Nilotinib—LCK—TCR signaling in naïve CD4+ T cells—HLA-DRB1—psoriatic arthritis	0.000371	0.0019	CbGpPWpGaD
Nilotinib—LCK—Signaling by Interleukins—NOD2—psoriatic arthritis	0.000368	0.00188	CbGpPWpGaD
Nilotinib—CA2—tendon—psoriatic arthritis	0.000364	0.0124	CbGeAlD
Nilotinib—LCK—Costimulation by the CD28 family—HLA-DRB1—psoriatic arthritis	0.000362	0.00185	CbGpPWpGaD
Nilotinib—MAPK14—Monoamine Transport—TNF—psoriatic arthritis	0.000362	0.00185	CbGpPWpGaD
Nilotinib—EPHA4—Spinal Cord Injury—TNF—psoriatic arthritis	0.000361	0.00185	CbGpPWpGaD
Nilotinib—MAPK14—Platelet homeostasis—NOS2—psoriatic arthritis	0.000357	0.00183	CbGpPWpGaD
Nilotinib—MAPK8—Downstream signaling in naïve CD8+ T cells—TNF—psoriatic arthritis	0.000357	0.00183	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—MEFV—psoriatic arthritis	0.000353	0.00181	CbGpPWpGaD
Nilotinib—MAPK14—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.000343	0.00176	CbGpPWpGaD
Nilotinib—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriatic arthritis	0.000342	0.00175	CbGpPWpGaD
Nilotinib—LCK—B Cell Activation—REL—psoriatic arthritis	0.000338	0.00173	CbGpPWpGaD
Nilotinib—LCK—DAP12 interactions—HLA-C—psoriatic arthritis	0.000337	0.00172	CbGpPWpGaD
Nilotinib—ABCB1—Allograft Rejection—HLA-C—psoriatic arthritis	0.000336	0.00172	CbGpPWpGaD
Nilotinib—ABCB1—Allograft Rejection—IL13—psoriatic arthritis	0.000334	0.00171	CbGpPWpGaD
Nilotinib—HCK—Immune System—MEFV—psoriatic arthritis	0.000334	0.00171	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—MEFV—psoriatic arthritis	0.000318	0.00163	CbGpPWpGaD
Nilotinib—MAPK14—Amyotrophic lateral sclerosis (ALS)—TNF—psoriatic arthritis	0.000315	0.00161	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—MEFV—psoriatic arthritis	0.000312	0.0016	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—MEFV—psoriatic arthritis	0.00031	0.00159	CbGpPWpGaD
Nilotinib—HCK—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.00031	0.00158	CbGpPWpGaD
Nilotinib—ABCB1—Allograft Rejection—IL17A—psoriatic arthritis	0.000307	0.00157	CbGpPWpGaD
Nilotinib—LCK—CXCR4-mediated signaling events—HLA-DRB1—psoriatic arthritis	0.000306	0.00157	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—MEFV—psoriatic arthritis	0.000303	0.00155	CbGpPWpGaD
Nilotinib—BLK—Immune System—MEFV—psoriatic arthritis	0.000303	0.00155	CbGpPWpGaD
Nilotinib—FGR—Immune System—MEFV—psoriatic arthritis	0.000302	0.00154	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—MEFV—psoriatic arthritis	0.000295	0.00151	CbGpPWpGaD
Nilotinib—MAPK8—Circadian rythm related genes—NOS2—psoriatic arthritis	0.000295	0.00151	CbGpPWpGaD
Nilotinib—MAPK8—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	0.000294	0.00151	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—HLA-C—psoriatic arthritis	0.000294	0.0015	CbGpPWpGaD
Nilotinib—MAPK14—TWEAK Signaling Pathway—TNF—psoriatic arthritis	0.000291	0.00149	CbGpPWpGaD
Nilotinib—KIT—DAP12 interactions—HLA-B—psoriatic arthritis	0.000291	0.00149	CbGpPWpGaD
Nilotinib—ABCB1—Allograft Rejection—IL12B—psoriatic arthritis	0.000286	0.00146	CbGpPWpGaD
Nilotinib—LYN—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000285	0.00146	CbGpPWpGaD
Nilotinib—BRAF—Downstream signaling in naïve CD8+ T cells—TNF—psoriatic arthritis	0.000281	0.00144	CbGpPWpGaD
Nilotinib—MAP2K5—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	0.00028	0.00143	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—REL—psoriatic arthritis	0.000278	0.00142	CbGpPWpGaD
Nilotinib—PDGFRA—DAP12 interactions—HLA-B—psoriatic arthritis	0.000275	0.00141	CbGpPWpGaD
Nilotinib—MAPK8—TNF alpha Signaling Pathway—TNF—psoriatic arthritis	0.000273	0.0014	CbGpPWpGaD
Nilotinib—Syncope—Betamethasone—psoriatic arthritis	0.000268	0.000681	CcSEcCtD
Nilotinib—Syncope—Dexamethasone—psoriatic arthritis	0.000268	0.000681	CcSEcCtD
Nilotinib—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	0.000267	0.00137	CbGpPWpGaD
Nilotinib—Arrhythmia—Prednisone—psoriatic arthritis	0.000267	0.000679	CcSEcCtD
Nilotinib—Infection—Triamcinolone—psoriatic arthritis	0.000267	0.000679	CcSEcCtD
Nilotinib—Infection—Methylprednisolone—psoriatic arthritis	0.000266	0.000677	CcSEcCtD
Nilotinib—MAPK8—Innate Immune System—HLA-C—psoriatic arthritis	0.000266	0.00136	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—HLA-C—psoriatic arthritis	0.000265	0.00136	CbGpPWpGaD
Nilotinib—Haematuria—Methotrexate—psoriatic arthritis	0.000265	0.000675	CcSEcCtD
Nilotinib—Shock—Triamcinolone—psoriatic arthritis	0.000264	0.000672	CcSEcCtD
Nilotinib—Insomnia—Prednisolone—psoriatic arthritis	0.000264	0.000672	CcSEcCtD
Nilotinib—Alopecia—Prednisone—psoriatic arthritis	0.000264	0.000672	CcSEcCtD
Nilotinib—Shock—Methylprednisolone—psoriatic arthritis	0.000264	0.000671	CcSEcCtD
Nilotinib—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.000263	0.000669	CcSEcCtD
Nilotinib—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000263	0.000669	CcSEcCtD
Nilotinib—Loss of consciousness—Betamethasone—psoriatic arthritis	0.000262	0.000668	CcSEcCtD
Nilotinib—Loss of consciousness—Dexamethasone—psoriatic arthritis	0.000262	0.000668	CcSEcCtD
Nilotinib—Epistaxis—Methotrexate—psoriatic arthritis	0.000262	0.000667	CcSEcCtD
Nilotinib—Paraesthesia—Prednisolone—psoriatic arthritis	0.000262	0.000667	CcSEcCtD
Nilotinib—HCK—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000262	0.00134	CbGpPWpGaD
Nilotinib—Tachycardia—Triamcinolone—psoriatic arthritis	0.000262	0.000667	CcSEcCtD
Nilotinib—Mental disorder—Prednisone—psoriatic arthritis	0.000262	0.000666	CcSEcCtD
Nilotinib—Tachycardia—Methylprednisolone—psoriatic arthritis	0.000261	0.000665	CcSEcCtD
Nilotinib—Skin disorder—Methylprednisolone—psoriatic arthritis	0.00026	0.000662	CcSEcCtD
Nilotinib—Erythema—Prednisone—psoriatic arthritis	0.00026	0.000662	CcSEcCtD
Nilotinib—Malnutrition—Prednisone—psoriatic arthritis	0.00026	0.000662	CcSEcCtD
Nilotinib—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.00026	0.000661	CcSEcCtD
Nilotinib—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.000259	0.000659	CcSEcCtD
Nilotinib—Hypertension—Betamethasone—psoriatic arthritis	0.000258	0.000656	CcSEcCtD
Nilotinib—Hypertension—Dexamethasone—psoriatic arthritis	0.000258	0.000656	CcSEcCtD
Nilotinib—LCK—Innate Immune System—MEFV—psoriatic arthritis	0.000255	0.00131	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000255	0.00131	CbGpPWpGaD
Nilotinib—Myalgia—Dexamethasone—psoriatic arthritis	0.000254	0.000647	CcSEcCtD
Nilotinib—Myalgia—Betamethasone—psoriatic arthritis	0.000254	0.000647	CcSEcCtD
Nilotinib—ABL1—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—psoriatic arthritis	0.000254	0.0013	CbGpPWpGaD
Nilotinib—MAPK14—Angiopoietin receptor Tie2-mediated signaling—TNF—psoriatic arthritis	0.000253	0.0013	CbGpPWpGaD
Nilotinib—Anxiety—Betamethasone—psoriatic arthritis	0.000253	0.000645	CcSEcCtD
Nilotinib—Anxiety—Dexamethasone—psoriatic arthritis	0.000253	0.000645	CcSEcCtD
Nilotinib—MAPK8—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	0.000252	0.00129	CbGpPWpGaD
Nilotinib—Discomfort—Dexamethasone—psoriatic arthritis	0.000251	0.000639	CcSEcCtD
Nilotinib—Discomfort—Betamethasone—psoriatic arthritis	0.000251	0.000639	CcSEcCtD
Nilotinib—Haemoglobin—Methotrexate—psoriatic arthritis	0.000251	0.000638	CcSEcCtD
Nilotinib—Hypotension—Methylprednisolone—psoriatic arthritis	0.00025	0.000637	CcSEcCtD
Nilotinib—Pain—Prednisolone—psoriatic arthritis	0.00025	0.000635	CcSEcCtD
Nilotinib—Hepatitis—Methotrexate—psoriatic arthritis	0.00025	0.000635	CcSEcCtD
Nilotinib—Haemorrhage—Methotrexate—psoriatic arthritis	0.00025	0.000635	CcSEcCtD
Nilotinib—PDGFRB—DAP12 interactions—HLA-B—psoriatic arthritis	0.000248	0.00127	CbGpPWpGaD
Nilotinib—Pharyngitis—Methotrexate—psoriatic arthritis	0.000248	0.00063	CcSEcCtD
Nilotinib—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.000246	0.000627	CcSEcCtD
Nilotinib—Vision blurred—Prednisone—psoriatic arthritis	0.000245	0.000624	CcSEcCtD
Nilotinib—Urethral disorder—Methotrexate—psoriatic arthritis	0.000245	0.000623	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.000245	0.000623	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.000244	0.000621	CcSEcCtD
Nilotinib—Oedema—Betamethasone—psoriatic arthritis	0.000244	0.00062	CcSEcCtD
Nilotinib—Oedema—Dexamethasone—psoriatic arthritis	0.000244	0.00062	CcSEcCtD
Nilotinib—MAP4K1—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000243	0.00124	CbGpPWpGaD
Nilotinib—Insomnia—Triamcinolone—psoriatic arthritis	0.000243	0.000618	CcSEcCtD
Nilotinib—Insomnia—Methylprednisolone—psoriatic arthritis	0.000242	0.000617	CcSEcCtD
Nilotinib—Infection—Dexamethasone—psoriatic arthritis	0.000242	0.000616	CcSEcCtD
Nilotinib—Infection—Betamethasone—psoriatic arthritis	0.000242	0.000616	CcSEcCtD
Nilotinib—Ill-defined disorder—Prednisone—psoriatic arthritis	0.000241	0.000614	CcSEcCtD
Nilotinib—MAPK11—Immune System—MEFV—psoriatic arthritis	0.000241	0.00123	CbGpPWpGaD
Nilotinib—Paraesthesia—Triamcinolone—psoriatic arthritis	0.000241	0.000614	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisolone—psoriatic arthritis	0.000241	0.000612	CcSEcCtD
Nilotinib—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.000241	0.000612	CcSEcCtD
Nilotinib—Visual impairment—Methotrexate—psoriatic arthritis	0.00024	0.000612	CcSEcCtD
Nilotinib—Anaemia—Prednisone—psoriatic arthritis	0.00024	0.000612	CcSEcCtD
Nilotinib—Shock—Dexamethasone—psoriatic arthritis	0.00024	0.00061	CcSEcCtD
Nilotinib—Shock—Betamethasone—psoriatic arthritis	0.00024	0.00061	CcSEcCtD
Nilotinib—Dyspnoea—Triamcinolone—psoriatic arthritis	0.000239	0.000609	CcSEcCtD
Nilotinib—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000239	0.000608	CcSEcCtD
Nilotinib—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000239	0.000608	CcSEcCtD
Nilotinib—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000239	0.000607	CcSEcCtD
Nilotinib—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000239	0.000607	CcSEcCtD
Nilotinib—Tachycardia—Dexamethasone—psoriatic arthritis	0.000238	0.000605	CcSEcCtD
Nilotinib—Tachycardia—Betamethasone—psoriatic arthritis	0.000238	0.000605	CcSEcCtD
Nilotinib—Dyspepsia—Triamcinolone—psoriatic arthritis	0.000236	0.000602	CcSEcCtD
Nilotinib—Erythema multiforme—Methotrexate—psoriatic arthritis	0.000236	0.000601	CcSEcCtD
Nilotinib—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.000236	0.0006	CcSEcCtD
Nilotinib—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.000235	0.000599	CcSEcCtD
Nilotinib—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.000235	0.000599	CcSEcCtD
Nilotinib—MAPK14—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	0.000235	0.0012	CbGpPWpGaD
Nilotinib—Malaise—Prednisone—psoriatic arthritis	0.000234	0.000597	CcSEcCtD
Nilotinib—Vertigo—Prednisone—psoriatic arthritis	0.000234	0.000594	CcSEcCtD
Nilotinib—LCK—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000233	0.00119	CbGpPWpGaD
Nilotinib—Eye disorder—Methotrexate—psoriatic arthritis	0.000233	0.000594	CcSEcCtD
Nilotinib—Syncope—Prednisone—psoriatic arthritis	0.000233	0.000593	CcSEcCtD
Nilotinib—Tinnitus—Methotrexate—psoriatic arthritis	0.000233	0.000592	CcSEcCtD
Nilotinib—Anorexia—Dexamethasone—psoriatic arthritis	0.000232	0.000591	CcSEcCtD
Nilotinib—Anorexia—Betamethasone—psoriatic arthritis	0.000232	0.000591	CcSEcCtD
Nilotinib—Urticaria—Prednisolone—psoriatic arthritis	0.000232	0.00059	CcSEcCtD
Nilotinib—Cardiac disorder—Methotrexate—psoriatic arthritis	0.000232	0.00059	CcSEcCtD
Nilotinib—Fatigue—Triamcinolone—psoriatic arthritis	0.000231	0.000589	CcSEcCtD
Nilotinib—Fatigue—Methylprednisolone—psoriatic arthritis	0.000231	0.000588	CcSEcCtD
Nilotinib—Pain—Triamcinolone—psoriatic arthritis	0.00023	0.000584	CcSEcCtD
Nilotinib—Loss of consciousness—Prednisone—psoriatic arthritis	0.000228	0.000582	CcSEcCtD
Nilotinib—Hypotension—Dexamethasone—psoriatic arthritis	0.000228	0.000579	CcSEcCtD
Nilotinib—Hypotension—Betamethasone—psoriatic arthritis	0.000228	0.000579	CcSEcCtD
Nilotinib—Angiopathy—Methotrexate—psoriatic arthritis	0.000226	0.000576	CcSEcCtD
Nilotinib—Immune system disorder—Methotrexate—psoriatic arthritis	0.000225	0.000574	CcSEcCtD
Nilotinib—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.000225	0.000572	CcSEcCtD
Nilotinib—Hypertension—Prednisone—psoriatic arthritis	0.000224	0.000571	CcSEcCtD
Nilotinib—Chills—Methotrexate—psoriatic arthritis	0.000224	0.00057	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.000222	0.000565	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.000222	0.000565	CcSEcCtD
Nilotinib—Myalgia—Prednisone—psoriatic arthritis	0.000221	0.000563	CcSEcCtD
Nilotinib—Arthralgia—Prednisone—psoriatic arthritis	0.000221	0.000563	CcSEcCtD
Nilotinib—Feeling abnormal—Triamcinolone—psoriatic arthritis	0.000221	0.000563	CcSEcCtD
Nilotinib—Feeling abnormal—Methylprednisolone—psoriatic arthritis	0.000221	0.000562	CcSEcCtD
Nilotinib—Anxiety—Prednisone—psoriatic arthritis	0.000221	0.000561	CcSEcCtD
Nilotinib—Alopecia—Methotrexate—psoriatic arthritis	0.000221	0.000561	CcSEcCtD
Nilotinib—Insomnia—Dexamethasone—psoriatic arthritis	0.00022	0.000561	CcSEcCtD
Nilotinib—Insomnia—Betamethasone—psoriatic arthritis	0.00022	0.000561	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.00022	0.000559	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000219	0.000558	CcSEcCtD
Nilotinib—Paraesthesia—Dexamethasone—psoriatic arthritis	0.000219	0.000557	CcSEcCtD
Nilotinib—Paraesthesia—Betamethasone—psoriatic arthritis	0.000219	0.000557	CcSEcCtD
Nilotinib—Discomfort—Prednisone—psoriatic arthritis	0.000219	0.000557	CcSEcCtD
Nilotinib—Mental disorder—Methotrexate—psoriatic arthritis	0.000219	0.000557	CcSEcCtD
Nilotinib—TEK—Hemostasis—NOS2—psoriatic arthritis	0.000218	0.00111	CbGpPWpGaD
Nilotinib—KIT—Immune System—MEFV—psoriatic arthritis	0.000217	0.00111	CbGpPWpGaD
Nilotinib—Erythema—Methotrexate—psoriatic arthritis	0.000217	0.000553	CcSEcCtD
Nilotinib—Malnutrition—Methotrexate—psoriatic arthritis	0.000217	0.000553	CcSEcCtD
Nilotinib—HCK—Innate Immune System—NOD2—psoriatic arthritis	0.000216	0.0011	CbGpPWpGaD
Nilotinib—Hypersensitivity—Prednisolone—psoriatic arthritis	0.000215	0.000548	CcSEcCtD
Nilotinib—Dyspepsia—Dexamethasone—psoriatic arthritis	0.000214	0.000546	CcSEcCtD
Nilotinib—Dyspepsia—Betamethasone—psoriatic arthritis	0.000214	0.000546	CcSEcCtD
Nilotinib—Urticaria—Triamcinolone—psoriatic arthritis	0.000213	0.000543	CcSEcCtD
Nilotinib—Urticaria—Methylprednisolone—psoriatic arthritis	0.000213	0.000542	CcSEcCtD
Nilotinib—Dysgeusia—Methotrexate—psoriatic arthritis	0.000213	0.000542	CcSEcCtD
Nilotinib—Body temperature increased—Triamcinolone—psoriatic arthritis	0.000212	0.00054	CcSEcCtD
Nilotinib—Oedema—Prednisone—psoriatic arthritis	0.000212	0.00054	CcSEcCtD
Nilotinib—MAPK11—Innate Immune System—HLA-C—psoriatic arthritis	0.000212	0.00108	CbGpPWpGaD
Nilotinib—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.000212	0.000539	CcSEcCtD
Nilotinib—Decreased appetite—Dexamethasone—psoriatic arthritis	0.000212	0.000539	CcSEcCtD
Nilotinib—Decreased appetite—Betamethasone—psoriatic arthritis	0.000212	0.000539	CcSEcCtD
Nilotinib—Infection—Prednisone—psoriatic arthritis	0.000211	0.000536	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.00021	0.000535	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.00021	0.000535	CcSEcCtD
Nilotinib—Back pain—Methotrexate—psoriatic arthritis	0.00021	0.000535	CcSEcCtD
Nilotinib—PDGFRA—Allograft Rejection—TNF—psoriatic arthritis	0.00021	0.00108	CbGpPWpGaD
Nilotinib—Fatigue—Betamethasone—psoriatic arthritis	0.00021	0.000535	CcSEcCtD
Nilotinib—Fatigue—Dexamethasone—psoriatic arthritis	0.00021	0.000535	CcSEcCtD
Nilotinib—LYN—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000209	0.00107	CbGpPWpGaD
Nilotinib—Shock—Prednisone—psoriatic arthritis	0.000209	0.000531	CcSEcCtD
Nilotinib—Pain—Dexamethasone—psoriatic arthritis	0.000208	0.00053	CcSEcCtD
Nilotinib—Pain—Betamethasone—psoriatic arthritis	0.000208	0.00053	CcSEcCtD
Nilotinib—Nervous system disorder—Prednisone—psoriatic arthritis	0.000208	0.00053	CcSEcCtD
Nilotinib—Tachycardia—Prednisone—psoriatic arthritis	0.000207	0.000527	CcSEcCtD
Nilotinib—Skin disorder—Prednisone—psoriatic arthritis	0.000206	0.000525	CcSEcCtD
Nilotinib—PDGFRA—Immune System—MEFV—psoriatic arthritis	0.000206	0.00105	CbGpPWpGaD
Nilotinib—Hyperhidrosis—Prednisone—psoriatic arthritis	0.000205	0.000522	CcSEcCtD
Nilotinib—Vision blurred—Methotrexate—psoriatic arthritis	0.000205	0.000521	CcSEcCtD
Nilotinib—Anorexia—Prednisone—psoriatic arthritis	0.000202	0.000515	CcSEcCtD
Nilotinib—Ill-defined disorder—Methotrexate—psoriatic arthritis	0.000202	0.000513	CcSEcCtD
Nilotinib—Anaemia—Methotrexate—psoriatic arthritis	0.000201	0.000511	CcSEcCtD
Nilotinib—Feeling abnormal—Dexamethasone—psoriatic arthritis	0.000201	0.000511	CcSEcCtD
Nilotinib—Feeling abnormal—Betamethasone—psoriatic arthritis	0.000201	0.000511	CcSEcCtD
Nilotinib—MAPK11—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	0.000201	0.00103	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—REL—psoriatic arthritis	0.000199	0.00102	CbGpPWpGaD
Nilotinib—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000199	0.000507	CcSEcCtD
Nilotinib—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000199	0.000507	CcSEcCtD
Nilotinib—LCK—DAP12 interactions—HLA-B—psoriatic arthritis	0.000199	0.00102	CbGpPWpGaD
Nilotinib—ABCB1—Allograft Rejection—HLA-B—psoriatic arthritis	0.000199	0.00102	CbGpPWpGaD
Nilotinib—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.000198	0.000504	CcSEcCtD
Nilotinib—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.000197	0.000502	CcSEcCtD
Nilotinib—MAPK8—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.000197	0.00101	CbGpPWpGaD
Nilotinib—Malaise—Methotrexate—psoriatic arthritis	0.000196	0.000499	CcSEcCtD
Nilotinib—MAPK8—Innate Immune System—NOD2—psoriatic arthritis	0.000196	0.001	CbGpPWpGaD
Nilotinib—Vertigo—Methotrexate—psoriatic arthritis	0.000195	0.000497	CcSEcCtD
Nilotinib—FGR—Innate Immune System—NOD2—psoriatic arthritis	0.000195	0.000998	CbGpPWpGaD
Nilotinib—Leukopenia—Methotrexate—psoriatic arthritis	0.000194	0.000495	CcSEcCtD
Nilotinib—Urticaria—Betamethasone—psoriatic arthritis	0.000194	0.000493	CcSEcCtD
Nilotinib—Urticaria—Dexamethasone—psoriatic arthritis	0.000194	0.000493	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.000193	0.000492	CcSEcCtD
Nilotinib—Dizziness—Prednisolone—psoriatic arthritis	0.000193	0.000491	CcSEcCtD
Nilotinib—Asthenia—Triamcinolone—psoriatic arthritis	0.000193	0.00049	CcSEcCtD
Nilotinib—Abdominal pain—Betamethasone—psoriatic arthritis	0.000193	0.00049	CcSEcCtD
Nilotinib—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000193	0.00049	CcSEcCtD
Nilotinib—Body temperature increased—Betamethasone—psoriatic arthritis	0.000193	0.00049	CcSEcCtD
Nilotinib—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000193	0.00049	CcSEcCtD
Nilotinib—Asthenia—Methylprednisolone—psoriatic arthritis	0.000192	0.000489	CcSEcCtD
Nilotinib—Insomnia—Prednisone—psoriatic arthritis	0.000192	0.000488	CcSEcCtD
Nilotinib—KIT—Innate Immune System—HLA-C—psoriatic arthritis	0.000191	0.000978	CbGpPWpGaD
Nilotinib—Paraesthesia—Prednisone—psoriatic arthritis	0.00019	0.000485	CcSEcCtD
Nilotinib—Pruritus—Triamcinolone—psoriatic arthritis	0.00019	0.000484	CcSEcCtD
Nilotinib—Cough—Methotrexate—psoriatic arthritis	0.00019	0.000483	CcSEcCtD
Nilotinib—Pruritus—Methylprednisolone—psoriatic arthritis	0.00019	0.000482	CcSEcCtD
Nilotinib—PDGFRA—Adaptive Immune System—REL—psoriatic arthritis	0.000189	0.000966	CbGpPWpGaD
Nilotinib—Dyspepsia—Prednisone—psoriatic arthritis	0.000187	0.000475	CcSEcCtD
Nilotinib—HCK—Immune System—REL—psoriatic arthritis	0.000186	0.000951	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—MEFV—psoriatic arthritis	0.000185	0.000949	CbGpPWpGaD
Nilotinib—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriatic arthritis	0.000185	0.000947	CbGpPWpGaD
Nilotinib—Arthralgia—Methotrexate—psoriatic arthritis	0.000185	0.000471	CcSEcCtD
Nilotinib—Myalgia—Methotrexate—psoriatic arthritis	0.000185	0.000471	CcSEcCtD
Nilotinib—Chest pain—Methotrexate—psoriatic arthritis	0.000185	0.000471	CcSEcCtD
Nilotinib—Decreased appetite—Prednisone—psoriatic arthritis	0.000184	0.000469	CcSEcCtD
Nilotinib—Rash—Prednisolone—psoriatic arthritis	0.000184	0.000469	CcSEcCtD
Nilotinib—Dermatitis—Prednisolone—psoriatic arthritis	0.000184	0.000468	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000184	0.000468	CcSEcCtD
Nilotinib—KIT—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000184	0.000939	CbGpPWpGaD
Nilotinib—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000183	0.000467	CcSEcCtD
Nilotinib—Fatigue—Prednisone—psoriatic arthritis	0.000183	0.000466	CcSEcCtD
Nilotinib—Headache—Prednisolone—psoriatic arthritis	0.000183	0.000466	CcSEcCtD
Nilotinib—Discomfort—Methotrexate—psoriatic arthritis	0.000183	0.000465	CcSEcCtD
Nilotinib—LYN—Immune System—MEFV—psoriatic arthritis	0.000182	0.000929	CbGpPWpGaD
Nilotinib—Constipation—Prednisone—psoriatic arthritis	0.000181	0.000462	CcSEcCtD
Nilotinib—PDGFRA—Innate Immune System—HLA-C—psoriatic arthritis	0.000181	0.000926	CbGpPWpGaD
Nilotinib—ABL1—Immune System—MEFV—psoriatic arthritis	0.000181	0.000925	CbGpPWpGaD
Nilotinib—MAPK8—Apoptosis—TNF—psoriatic arthritis	0.00018	0.000922	CbGpPWpGaD
Nilotinib—Confusional state—Methotrexate—psoriatic arthritis	0.000179	0.000455	CcSEcCtD
Nilotinib—Dizziness—Triamcinolone—psoriatic arthritis	0.000178	0.000452	CcSEcCtD
Nilotinib—Dizziness—Methylprednisolone—psoriatic arthritis	0.000177	0.000451	CcSEcCtD
Nilotinib—Infection—Methotrexate—psoriatic arthritis	0.000176	0.000448	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisone—psoriatic arthritis	0.000175	0.000445	CcSEcCtD
Nilotinib—Asthenia—Dexamethasone—psoriatic arthritis	0.000175	0.000445	CcSEcCtD
Nilotinib—Asthenia—Betamethasone—psoriatic arthritis	0.000175	0.000445	CcSEcCtD
Nilotinib—Nervous system disorder—Methotrexate—psoriatic arthritis	0.000174	0.000443	CcSEcCtD
Nilotinib—PDGFRA—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000174	0.000889	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—HLA-B—psoriatic arthritis	0.000174	0.000889	CbGpPWpGaD
Nilotinib—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.000174	0.000442	CcSEcCtD
Nilotinib—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000173	0.000442	CcSEcCtD
Nilotinib—Nausea—Prednisolone—psoriatic arthritis	0.000173	0.000441	CcSEcCtD
Nilotinib—Pruritus—Betamethasone—psoriatic arthritis	0.000172	0.000439	CcSEcCtD
Nilotinib—Pruritus—Dexamethasone—psoriatic arthritis	0.000172	0.000439	CcSEcCtD
Nilotinib—Skin disorder—Methotrexate—psoriatic arthritis	0.000172	0.000438	CcSEcCtD
Nilotinib—MAPK14—Immune System—MEFV—psoriatic arthritis	0.000172	0.000881	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000172	0.000878	CbGpPWpGaD
Nilotinib—Hyperhidrosis—Methotrexate—psoriatic arthritis	0.000171	0.000436	CcSEcCtD
Nilotinib—HCK—Immune System—HLA-C—psoriatic arthritis	0.000171	0.000875	CbGpPWpGaD
Nilotinib—Vomiting—Triamcinolone—psoriatic arthritis	0.000171	0.000435	CcSEcCtD
Nilotinib—Vomiting—Methylprednisolone—psoriatic arthritis	0.00017	0.000434	CcSEcCtD
Nilotinib—PDGFRB—Adaptive Immune System—REL—psoriatic arthritis	0.00017	0.00087	CbGpPWpGaD
Nilotinib—Rash—Triamcinolone—psoriatic arthritis	0.000169	0.000431	CcSEcCtD
Nilotinib—Dermatitis—Triamcinolone—psoriatic arthritis	0.000169	0.00043	CcSEcCtD
Nilotinib—Anorexia—Methotrexate—psoriatic arthritis	0.000169	0.00043	CcSEcCtD
Nilotinib—Rash—Methylprednisolone—psoriatic arthritis	0.000169	0.00043	CcSEcCtD
Nilotinib—MAPK8—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000169	0.000864	CbGpPWpGaD
Nilotinib—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000169	0.00043	CcSEcCtD
Nilotinib—Urticaria—Prednisone—psoriatic arthritis	0.000169	0.000429	CcSEcCtD
Nilotinib—MAPK8—Immune System—REL—psoriatic arthritis	0.000168	0.000862	CbGpPWpGaD
Nilotinib—BLK—Immune System—REL—psoriatic arthritis	0.000168	0.000862	CbGpPWpGaD
Nilotinib—ABCB1—Allograft Rejection—HLA-DRB1—psoriatic arthritis	0.000168	0.000861	CbGpPWpGaD
Nilotinib—LYN—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000168	0.000861	CbGpPWpGaD
Nilotinib—Headache—Triamcinolone—psoriatic arthritis	0.000168	0.000428	CcSEcCtD
Nilotinib—Headache—Methylprednisolone—psoriatic arthritis	0.000168	0.000427	CcSEcCtD
Nilotinib—FGR—Immune System—REL—psoriatic arthritis	0.000168	0.000859	CbGpPWpGaD
Nilotinib—Abdominal pain—Prednisone—psoriatic arthritis	0.000168	0.000427	CcSEcCtD
Nilotinib—Body temperature increased—Prednisone—psoriatic arthritis	0.000168	0.000427	CcSEcCtD
Nilotinib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	0.000167	0.000856	CbGpPWpGaD
Nilotinib—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000167	0.000424	CcSEcCtD
Nilotinib—Diarrhoea—Betamethasone—psoriatic arthritis	0.000167	0.000424	CcSEcCtD
Nilotinib—LYN—Adaptive Immune System—REL—psoriatic arthritis	0.000166	0.000852	CbGpPWpGaD
Nilotinib—Hypotension—Methotrexate—psoriatic arthritis	0.000166	0.000422	CcSEcCtD
Nilotinib—PDGFRB—Innate Immune System—HLA-C—psoriatic arthritis	0.000163	0.000834	CbGpPWpGaD
Nilotinib—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.000162	0.000411	CcSEcCtD
Nilotinib—Dizziness—Betamethasone—psoriatic arthritis	0.000161	0.00041	CcSEcCtD
Nilotinib—Dizziness—Dexamethasone—psoriatic arthritis	0.000161	0.00041	CcSEcCtD
Nilotinib—MAP2K5—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000161	0.000822	CbGpPWpGaD
Nilotinib—Insomnia—Methotrexate—psoriatic arthritis	0.00016	0.000408	CcSEcCtD
Nilotinib—LYN—Innate Immune System—HLA-C—psoriatic arthritis	0.00016	0.000817	CbGpPWpGaD
Nilotinib—Nausea—Triamcinolone—psoriatic arthritis	0.000159	0.000406	CcSEcCtD
Nilotinib—Paraesthesia—Methotrexate—psoriatic arthritis	0.000159	0.000405	CcSEcCtD
Nilotinib—Nausea—Methylprednisolone—psoriatic arthritis	0.000159	0.000405	CcSEcCtD
Nilotinib—ABL1—Innate Immune System—HLA-C—psoriatic arthritis	0.000159	0.000813	CbGpPWpGaD
Nilotinib—Dyspnoea—Methotrexate—psoriatic arthritis	0.000158	0.000402	CcSEcCtD
Nilotinib—MAPK8—Innate Immune System—HLA-B—psoriatic arthritis	0.000157	0.000805	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—HLA-B—psoriatic arthritis	0.000157	0.000802	CbGpPWpGaD
Nilotinib—MAPK11—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.000157	0.000802	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000156	0.000801	CbGpPWpGaD
Nilotinib—Hypersensitivity—Prednisone—psoriatic arthritis	0.000156	0.000398	CcSEcCtD
Nilotinib—Dyspepsia—Methotrexate—psoriatic arthritis	0.000156	0.000397	CcSEcCtD
Nilotinib—MAPK11—Innate Immune System—NOD2—psoriatic arthritis	0.000156	0.000798	CbGpPWpGaD
Nilotinib—BLK—Immune System—HLA-C—psoriatic arthritis	0.000155	0.000793	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—HLA-C—psoriatic arthritis	0.000155	0.000793	CbGpPWpGaD
Nilotinib—Vomiting—Betamethasone—psoriatic arthritis	0.000155	0.000394	CcSEcCtD
Nilotinib—Vomiting—Dexamethasone—psoriatic arthritis	0.000155	0.000394	CcSEcCtD
Nilotinib—FGR—Immune System—HLA-C—psoriatic arthritis	0.000154	0.00079	CbGpPWpGaD
Nilotinib—Decreased appetite—Methotrexate—psoriatic arthritis	0.000154	0.000392	CcSEcCtD
Nilotinib—Rash—Dexamethasone—psoriatic arthritis	0.000154	0.000391	CcSEcCtD
Nilotinib—Rash—Betamethasone—psoriatic arthritis	0.000154	0.000391	CcSEcCtD
Nilotinib—Dermatitis—Betamethasone—psoriatic arthritis	0.000153	0.000391	CcSEcCtD
Nilotinib—Dermatitis—Dexamethasone—psoriatic arthritis	0.000153	0.000391	CcSEcCtD
Nilotinib—HCK—Innate Immune System—CRP—psoriatic arthritis	0.000153	0.000785	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000153	0.000784	CbGpPWpGaD
Nilotinib—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000153	0.00039	CcSEcCtD
Nilotinib—Fatigue—Methotrexate—psoriatic arthritis	0.000153	0.000389	CcSEcCtD
Nilotinib—Headache—Dexamethasone—psoriatic arthritis	0.000153	0.000388	CcSEcCtD
Nilotinib—Headache—Betamethasone—psoriatic arthritis	0.000153	0.000388	CcSEcCtD
Nilotinib—MAPK8—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000152	0.00078	CbGpPWpGaD
Nilotinib—Asthenia—Prednisone—psoriatic arthritis	0.000152	0.000387	CcSEcCtD
Nilotinib—Pain—Methotrexate—psoriatic arthritis	0.000152	0.000386	CcSEcCtD
Nilotinib—MAPK14—Innate Immune System—HLA-C—psoriatic arthritis	0.000151	0.000774	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000151	0.000773	CbGpPWpGaD
Nilotinib—Pruritus—Prednisone—psoriatic arthritis	0.00015	0.000382	CcSEcCtD
Nilotinib—LCK—Immune System—MEFV—psoriatic arthritis	0.000149	0.000762	CbGpPWpGaD
Nilotinib—Feeling abnormal—Methotrexate—psoriatic arthritis	0.000146	0.000372	CcSEcCtD
Nilotinib—Diarrhoea—Prednisone—psoriatic arthritis	0.000145	0.000369	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.000145	0.000369	CcSEcCtD
Nilotinib—Nausea—Dexamethasone—psoriatic arthritis	0.000145	0.000368	CcSEcCtD
Nilotinib—Nausea—Betamethasone—psoriatic arthritis	0.000145	0.000368	CcSEcCtD
Nilotinib—MAPK14—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	0.000143	0.000733	CbGpPWpGaD
Nilotinib—LYN—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000142	0.000729	CbGpPWpGaD
Nilotinib—Urticaria—Methotrexate—psoriatic arthritis	0.000141	0.000359	CcSEcCtD
Nilotinib—KIT—Innate Immune System—NOD2—psoriatic arthritis	0.000141	0.000719	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—NOS2—psoriatic arthritis	0.00014	0.000718	CbGpPWpGaD
Nilotinib—Dizziness—Prednisone—psoriatic arthritis	0.00014	0.000357	CcSEcCtD
Nilotinib—Abdominal pain—Methotrexate—psoriatic arthritis	0.00014	0.000357	CcSEcCtD
Nilotinib—Body temperature increased—Methotrexate—psoriatic arthritis	0.00014	0.000357	CcSEcCtD
Nilotinib—MAPK8—Innate Immune System—CRP—psoriatic arthritis	0.000139	0.000712	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—CRP—psoriatic arthritis	0.000139	0.000709	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000138	0.000706	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—REL—psoriatic arthritis	0.000136	0.000698	CbGpPWpGaD
Nilotinib—EPHB3—Developmental Biology—TNF—psoriatic arthritis	0.000135	0.000692	CbGpPWpGaD
Nilotinib—Vomiting—Prednisone—psoriatic arthritis	0.000135	0.000343	CcSEcCtD
Nilotinib—MAPK11—Immune System—REL—psoriatic arthritis	0.000134	0.000687	CbGpPWpGaD
Nilotinib—Rash—Prednisone—psoriatic arthritis	0.000134	0.00034	CcSEcCtD
Nilotinib—Dermatitis—Prednisone—psoriatic arthritis	0.000134	0.00034	CcSEcCtD
Nilotinib—BRAF—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000133	0.000682	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—NOD2—psoriatic arthritis	0.000133	0.000681	CbGpPWpGaD
Nilotinib—Headache—Prednisone—psoriatic arthritis	0.000133	0.000338	CcSEcCtD
Nilotinib—LCK—Innate Immune System—HLA-C—psoriatic arthritis	0.000131	0.000669	CbGpPWpGaD
Nilotinib—Hypersensitivity—Methotrexate—psoriatic arthritis	0.000131	0.000333	CcSEcCtD
Nilotinib—BLK—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000128	0.000654	CbGpPWpGaD
Nilotinib—Asthenia—Methotrexate—psoriatic arthritis	0.000127	0.000324	CcSEcCtD
Nilotinib—Nausea—Prednisone—psoriatic arthritis	0.000126	0.000321	CcSEcCtD
Nilotinib—HCK—Immune System—NOD2—psoriatic arthritis	0.000126	0.000644	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000126	0.000643	CbGpPWpGaD
Nilotinib—Pruritus—Methotrexate—psoriatic arthritis	0.000125	0.000319	CcSEcCtD
Nilotinib—MAPK11—Innate Immune System—HLA-B—psoriatic arthritis	0.000125	0.000641	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—HLA-C—psoriatic arthritis	0.000123	0.000632	CbGpPWpGaD
Nilotinib—Diarrhoea—Methotrexate—psoriatic arthritis	0.000121	0.000309	CcSEcCtD
Nilotinib—KIT—Immune System—REL—psoriatic arthritis	0.000121	0.000619	CbGpPWpGaD
Nilotinib—ABL2—Developmental Biology—TNF—psoriatic arthritis	0.000121	0.000617	CbGpPWpGaD
Nilotinib—EPHA3—Developmental Biology—TNF—psoriatic arthritis	0.000121	0.000617	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—NOD2—psoriatic arthritis	0.00012	0.000613	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—NOD2—psoriatic arthritis	0.000117	0.000601	CbGpPWpGaD
Nilotinib—Dizziness—Methotrexate—psoriatic arthritis	0.000117	0.000298	CcSEcCtD
Nilotinib—ABL1—Innate Immune System—NOD2—psoriatic arthritis	0.000117	0.000598	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000117	0.000598	CbGpPWpGaD
Nilotinib—EPHA8—Developmental Biology—TNF—psoriatic arthritis	0.000116	0.000595	CbGpPWpGaD
Nilotinib—EPHA4—Developmental Biology—TNF—psoriatic arthritis	0.000115	0.000588	CbGpPWpGaD
Nilotinib—EPHB4—Developmental Biology—TNF—psoriatic arthritis	0.000115	0.000588	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—REL—psoriatic arthritis	0.000114	0.000586	CbGpPWpGaD
Nilotinib—BLK—Immune System—NOD2—psoriatic arthritis	0.000114	0.000583	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—NOD2—psoriatic arthritis	0.000114	0.000583	CbGpPWpGaD
Nilotinib—FGR—Immune System—NOD2—psoriatic arthritis	0.000114	0.000581	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—HLA-B—psoriatic arthritis	0.000113	0.000578	CbGpPWpGaD
Nilotinib—Vomiting—Methotrexate—psoriatic arthritis	0.000113	0.000287	CcSEcCtD
Nilotinib—Rash—Methotrexate—psoriatic arthritis	0.000112	0.000285	CcSEcCtD
Nilotinib—MAPK14—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.000112	0.000572	CbGpPWpGaD
Nilotinib—Dermatitis—Methotrexate—psoriatic arthritis	0.000112	0.000284	CcSEcCtD
Nilotinib—EPHB2—Developmental Biology—TNF—psoriatic arthritis	0.000111	0.00057	CbGpPWpGaD
Nilotinib—KIT—Immune System—HLA-C—psoriatic arthritis	0.000111	0.00057	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—NOD2—psoriatic arthritis	0.000111	0.000569	CbGpPWpGaD
Nilotinib—Headache—Methotrexate—psoriatic arthritis	0.000111	0.000283	CcSEcCtD
Nilotinib—MAPK11—Innate Immune System—CRP—psoriatic arthritis	0.000111	0.000567	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000109	0.000555	CbGpPWpGaD
Nilotinib—EPHB6—Developmental Biology—TNF—psoriatic arthritis	0.000108	0.000553	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—HLA-B—psoriatic arthritis	0.000107	0.000548	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HLA-C—psoriatic arthritis	0.000105	0.000539	CbGpPWpGaD
Nilotinib—Nausea—Methotrexate—psoriatic arthritis	0.000105	0.000268	CcSEcCtD
Nilotinib—PDGFRA—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000104	0.000531	CbGpPWpGaD
Nilotinib—PDGFRB—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000103	0.00053	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—REL—psoriatic arthritis	0.000103	0.000528	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000103	0.000526	CbGpPWpGaD
Nilotinib—EPHA6—Developmental Biology—TNF—psoriatic arthritis	0.000102	0.00052	CbGpPWpGaD
Nilotinib—HCK—Immune System—HLA-B—psoriatic arthritis	0.000101	0.000518	CbGpPWpGaD
Nilotinib—LYN—Immune System—REL—psoriatic arthritis	0.000101	0.000517	CbGpPWpGaD
Nilotinib—ABL1—Immune System—REL—psoriatic arthritis	0.000101	0.000514	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—CRP—psoriatic arthritis	9.99e-05	0.000511	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—HLA-B—psoriatic arthritis	9.64e-05	0.000493	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—NOD2—psoriatic arthritis	9.62e-05	0.000492	CbGpPWpGaD
Nilotinib—MAPK14—MAPK Signaling Pathway—TNF—psoriatic arthritis	9.6e-05	0.000492	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—REL—psoriatic arthritis	9.57e-05	0.00049	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HLA-C—psoriatic arthritis	9.49e-05	0.000486	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—CRP—psoriatic arthritis	9.46e-05	0.000484	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—HLA-B—psoriatic arthritis	9.44e-05	0.000483	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—HLA-B—psoriatic arthritis	9.39e-05	0.000481	CbGpPWpGaD
Nilotinib—EPHA2—Developmental Biology—TNF—psoriatic arthritis	9.37e-05	0.00048	CbGpPWpGaD
Nilotinib—LYN—Immune System—HLA-C—psoriatic arthritis	9.29e-05	0.000476	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—HLA-B—psoriatic arthritis	9.25e-05	0.000474	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HLA-C—psoriatic arthritis	9.25e-05	0.000473	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	9.19e-05	0.00047	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—HLA-B—psoriatic arthritis	9.16e-05	0.000469	CbGpPWpGaD
Nilotinib—BLK—Immune System—HLA-B—psoriatic arthritis	9.16e-05	0.000469	CbGpPWpGaD
Nilotinib—FGR—Immune System—HLA-B—psoriatic arthritis	9.13e-05	0.000467	CbGpPWpGaD
Nilotinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	9.1e-05	0.000466	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—NOD2—psoriatic arthritis	9.08e-05	0.000465	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—HLA-B—psoriatic arthritis	9.06e-05	0.000464	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—HLA-B—psoriatic arthritis	8.94e-05	0.000458	CbGpPWpGaD
Nilotinib—HCK—Immune System—CRP—psoriatic arthritis	8.94e-05	0.000457	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HLA-C—psoriatic arthritis	8.81e-05	0.000451	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	8.7e-05	0.000445	CbGpPWpGaD
Nilotinib—MAPK14—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	8.67e-05	0.000444	CbGpPWpGaD
Nilotinib—HCK—Immune System—HLA-DRB1—psoriatic arthritis	8.56e-05	0.000438	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—CRP—psoriatic arthritis	8.52e-05	0.000436	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—NOS2—psoriatic arthritis	8.45e-05	0.000432	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—NOS2—psoriatic arthritis	8.41e-05	0.00043	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—CRP—psoriatic arthritis	8.34e-05	0.000427	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—CRP—psoriatic arthritis	8.3e-05	0.000425	CbGpPWpGaD
Nilotinib—LCK—Immune System—REL—psoriatic arthritis	8.28e-05	0.000424	CbGpPWpGaD
Nilotinib—KIT—Immune System—NOD2—psoriatic arthritis	8.19e-05	0.000419	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—CRP—psoriatic arthritis	8.1e-05	0.000414	CbGpPWpGaD
Nilotinib—BLK—Immune System—CRP—psoriatic arthritis	8.1e-05	0.000414	CbGpPWpGaD
Nilotinib—FGR—Immune System—CRP—psoriatic arthritis	8.07e-05	0.000413	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—NOS2—psoriatic arthritis	8.01e-05	0.00041	CbGpPWpGaD
Nilotinib—ABCB1—Allograft Rejection—TNF—psoriatic arthritis	7.95e-05	0.000407	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—CRP—psoriatic arthritis	7.91e-05	0.000405	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	7.83e-05	0.000401	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—HLA-DRB1—psoriatic arthritis	7.75e-05	0.000397	CbGpPWpGaD
Nilotinib—BLK—Immune System—HLA-DRB1—psoriatic arthritis	7.75e-05	0.000397	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—NOD2—psoriatic arthritis	7.75e-05	0.000397	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—HLA-B—psoriatic arthritis	7.73e-05	0.000396	CbGpPWpGaD
Nilotinib—FGR—Immune System—HLA-DRB1—psoriatic arthritis	7.73e-05	0.000396	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	7.67e-05	0.000393	CbGpPWpGaD
Nilotinib—LCK—Immune System—HLA-C—psoriatic arthritis	7.62e-05	0.00039	CbGpPWpGaD
Nilotinib—HCK—Disease—NOS2—psoriatic arthritis	7.52e-05	0.000385	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—HLA-B—psoriatic arthritis	7.43e-05	0.00038	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—HLA-B—psoriatic arthritis	7.3e-05	0.000374	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—NOD2—psoriatic arthritis	6.98e-05	0.000357	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—NOS2—psoriatic arthritis	6.92e-05	0.000354	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—CRP—psoriatic arthritis	6.84e-05	0.00035	CbGpPWpGaD
Nilotinib—LYN—Immune System—NOD2—psoriatic arthritis	6.83e-05	0.00035	CbGpPWpGaD
Nilotinib—ABL1—Immune System—NOD2—psoriatic arthritis	6.8e-05	0.000348	CbGpPWpGaD
Nilotinib—KIT—Immune System—HLA-B—psoriatic arthritis	6.58e-05	0.000337	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—NOD2—psoriatic arthritis	6.48e-05	0.000332	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CRP—psoriatic arthritis	6.45e-05	0.00033	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	6.29e-05	0.000322	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HLA-B—psoriatic arthritis	6.23e-05	0.000319	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—HLA-DRB1—psoriatic arthritis	6.18e-05	0.000316	CbGpPWpGaD
Nilotinib—KIT—Immune System—CRP—psoriatic arthritis	5.82e-05	0.000298	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—TNF—psoriatic arthritis	5.68e-05	0.000291	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HLA-B—psoriatic arthritis	5.61e-05	0.000287	CbGpPWpGaD
Nilotinib—LCK—Immune System—NOD2—psoriatic arthritis	5.6e-05	0.000287	CbGpPWpGaD
Nilotinib—KIT—Immune System—HLA-DRB1—psoriatic arthritis	5.57e-05	0.000285	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CRP—psoriatic arthritis	5.51e-05	0.000282	CbGpPWpGaD
Nilotinib—LYN—Immune System—HLA-B—psoriatic arthritis	5.5e-05	0.000281	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HLA-B—psoriatic arthritis	5.47e-05	0.00028	CbGpPWpGaD
Nilotinib—BRAF—Disease—NOS2—psoriatic arthritis	5.38e-05	0.000275	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HLA-DRB1—psoriatic arthritis	5.27e-05	0.00027	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HLA-B—psoriatic arthritis	5.21e-05	0.000267	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CRP—psoriatic arthritis	4.96e-05	0.000254	CbGpPWpGaD
Nilotinib—KIT—Disease—NOS2—psoriatic arthritis	4.9e-05	0.000251	CbGpPWpGaD
Nilotinib—LYN—Immune System—CRP—psoriatic arthritis	4.86e-05	0.000249	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CRP—psoriatic arthritis	4.83e-05	0.000247	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HLA-DRB1—psoriatic arthritis	4.75e-05	0.000243	CbGpPWpGaD
Nilotinib—LYN—Immune System—HLA-DRB1—psoriatic arthritis	4.65e-05	0.000238	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—NOS2—psoriatic arthritis	4.64e-05	0.000237	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HLA-DRB1—psoriatic arthritis	4.63e-05	0.000237	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CRP—psoriatic arthritis	4.6e-05	0.000236	CbGpPWpGaD
Nilotinib—LCK—Immune System—HLA-B—psoriatic arthritis	4.5e-05	0.000231	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HLA-DRB1—psoriatic arthritis	4.41e-05	0.000226	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—TNF—psoriatic arthritis	4.27e-05	0.000219	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—TNF—psoriatic arthritis	4.25e-05	0.000218	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—NOS2—psoriatic arthritis	4.18e-05	0.000214	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—TNF—psoriatic arthritis	4.05e-05	0.000207	CbGpPWpGaD
Nilotinib—LCK—Immune System—CRP—psoriatic arthritis	3.98e-05	0.000204	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	3.92e-05	0.000201	CbGpPWpGaD
Nilotinib—LCK—Immune System—HLA-DRB1—psoriatic arthritis	3.81e-05	0.000195	CbGpPWpGaD
Nilotinib—LCK—Disease—NOS2—psoriatic arthritis	3.35e-05	0.000172	CbGpPWpGaD
